The Pharma LetterGlaxo’s Cancer Medicine Fails to Meet Goal of Late-Stage TrialBusinessweekGlaxoSmithKline Plc (GSK)’s MAGE-A3 experimental cancer treatment failed to benefit lung cancer patients in a late-stage clinical trial. The therapy didn’t help patients with non-small cell lung cancer live longer without the disease recurring, the …GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trialThe Pharma LetterGlaxoSmithKline’s cancer vaccine MAGE A-3 suffers its second PhIII flopFierceBiotechCancer vaccine fails in second study…New VisionWall Street Journalall 26 news articles …read more
Via: Google UK
Glaxo's Cancer Medicine Fails to Meet Goal of Late-Stage Trial - Businessweek
Real Estate of Cebu
